Business NewsPR NewsWire • Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications

Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications

Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications

EAST HANOVER, N.J., Jan. 11 /PRNewswire/ -- Novartis announced that Fanapt(TM) (iloperidone) tablets are now available for use across the US for the acute treatment of schizophrenia in adults. Fanapt is a twice-daily, oral antipsychotic, approved by the US Food and Drug Administration (FDA) in May 2009.

View More : http://www.prnewswire.com/news-releases/novartis-launches-schizophrenia-treatment-fanapt-in-the-us-offering-patients-an-...
Releted News by prnewswire
Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil
Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Misys Launches New Solution for Personal Internet Banking